Tarnoff Michael E 4

What Happened Michael E. Tarnoff, a director of AVITA Medical, received equity awards that the company reports as (A) awards/grants: 48,464 restricted stock units (RSUs) and options covering 35,196 shares. The option grants carry exercise prices of $5.36 (19,063 options, grant date Aug 6, 2025) and $3.77 (16,133 options, grant date Jan 20, 2026). The RSU grants were for 26,250 shares (Aug 6, 2025) and 22,214 shares (Jan 20, 2026). The Form 4 records the derivative/option amounts at $0 (typical for newly issued option awards) and shows shareholder approval was obtained on June 3, 2026.

Key Details

• Transaction dates listed: Aug 6, 2025 (26,250 RSUs; 19,063 options) and Jan 20, 2026 (22,214 RSUs; 16,133 options).
• Shareholder approval for these grants was obtained on June 3, 2026; Form 4 filed June 4, 2026 (period of report 2026-06-03).
• Option exercise prices: $5.36 (Aug 6, 2025 grant) and $3.77 (Jan 20, 2026 grant).
• Vesting: RSUs vest in three equal annual installments beginning 12 months after the grant; options vest in three equal annual installments beginning the first anniversary of the grant.
• Shares owned after the transactions are not specified in the provided filing excerpt.
• Transaction code: A = Award/Grant; derivative awards shown with $0 reported value (common for grant reporting).
• Filing appears timely relative to the shareholder approval date (filed the next business day).

Context These are grant-type awards (not open-market purchases or sales). RSUs are a promise to issue shares subject to vesting; stock options give the right to buy shares at the stated exercise prices and will only create an immediate economic interest if exercised (and possibly sold). Such awards are routine compensation for directors and do not, by themselves, indicate a near-term purchase or sale of shares.